{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-051383","form_type":"8-K","ticker":"AKTX","cik":"0001541157","company_name":"Akari Therapeutics Plc","filed_at":"2024-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.905369+00:00","generated_at":"2026-06-03T02:48:23.888381+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Akari Therapeutics CEO and COO exit; merger portfolio prioritizes ADC and GA over other programs","bullets":["Rachelle Jacques stepped down as CEO effective May 1; COO Melissa Bradford-Klug terminated without cause same date.","Board member Samir Patel appointed interim CEO; compensated $50k monthly in RSUs.","Interim CFO DiCicco gets $40k/month, 45% bonus, transaction bonus, and 1% RSU grant.","Merger with Peak Bio to focus on ADC platform (TROP-2) and PAS-nomacopan for Geographic Atrophy.","HSCT-TMA program suspended, PHP 303 discontinued; merger expected close Q3 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-051383","json":"https://secwatch.observer/filing/0000950170-24-051383.json","markdown":"https://secwatch.observer/filing/0000950170-24-051383.md","text":"https://secwatch.observer/filing/0000950170-24-051383.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024051383/0000950170-24-051383-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024051383/aktx-20240425.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T02:48:23.888381+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3bda71a1de","claim":"Melissa Bradford-Klug departed as Chief Operating Officer at Akari Therapeutics Plc.","evidence_excerpt":"our Chief Operating Officer, Melissa Bradford-Klug, was terminated without cause, effective May 1, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024051383/0000950170-24-051383-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated without cause"},{"label":"Role","value":"Chief Operating Officer"}],"fact_type":"executive_change"},{"claim_id":"7ad27db704","claim":"Rachelle Jacques departed as President and Chief Executive Officer at Akari Therapeutics Plc.","evidence_excerpt":"Rachelle Jacques stepped down as the President and Chief Executive Officer of Akari Therapeutics, Plc (the “Company”), effective May 1, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024051383/0000950170-24-051383-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"9cba533798","claim":"Samir R. Patel was appointed as Interim President and Chief Executive Officer at Akari Therapeutics Plc.","evidence_excerpt":"the Board appointed Samir R. Patel, M.D., a member of the Board, to Interim President and Chief Executive Officer, effective May 1, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1541157/000095017024051383/0000950170-24-051383-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}